サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1781961

ウイルスベクターワクチン市場：疾患別、タイプ別、エンドユーザー別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測

Viral Vector Vaccines Market, By Disease, By Type, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 269 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
ウイルスベクターワクチン市場：疾患別、タイプ別、エンドユーザー別、国別、地域別-2025～2032年の世界産業分析、市場規模、市場シェア、予測
出版日: 2025年06月04日
発行: AnalystView Market Insights
ページ情報: 英文 269 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートのハイライト

ウイルスベクタワクチン市場規模は2024年に8億5,043万米ドルとなり、2025～2032年にかけてCAGR 15.93%で拡大

ウイルスベクタワクチン市場-市場力学

感染症の流行増加が市場需要を促進

COVID-19、インフルエンザ、肝炎などの感染症罹患率の上昇が、効果的なワクチンの需要を促進しています。世界保健機関（WHO）によると、ワクチンは年間200万～300万人の死亡を予防しており、世界保健におけるワクチンの重要な役割が浮き彫りになっています。さらに、遺伝子工学の絶え間ない進歩により、より効率的なウイルスベクタワクチンの開発が促進されています。しかし、稀ではあるが副作用の報告もあり、一般市民の躊躇を招き、今後数年間の市場成長の妨げになると予測されます。一方、開発途上地域は、ヘルスケアインフラの改善やワクチン接種に対する意識の高まりにより、大きな成長機会をもたらしています。

ウイルスベクタワクチン市場-主要な洞察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2025～2032年）に約15.93%のCAGRで毎年成長すると予測されます。

疾患別では、感染症が2024年に最大の市場シェアを示すと予測されました。

タイプ別では、アデノウイルスが2024年の主要タイプです。

地域別では、北米が2024年の売上高でトップ

ウイルスベクタワクチン市場-セグメンテーション分析

ウイルスベクタワクチンの世界市場は、疾患、タイプ、エンドユーザー、地域別に区分されます。

疾患別では、感染症、がん、遺伝性疾患、その他の4つに分類されます。感染症セグメントは、予測期間中、世界のウイルスベクタワクチン市場で主要な市場シェアを占めると予想されます。この優位性は主に、感染症の世界の負担の大きさと、感染症に対するワクチン開発におけるウイルスベクタプラットフォームの有効性が実証されていることに起因しています。

市場は、アデノ随伴ウイルス（AAV）、アデノウイルス、レンチウイルス、レトロウイルス、その他の5つのカテゴリーに分類されます。予測期間中、アデノウイルスセグメントが最大の市場シェアを占めると予想されます。これは主に、アデノウイルスがその強い免疫原性、大きな遺伝子ペイロードを運ぶ能力、迅速なワクチン開発に適していることから広く使用されているためです。

ウイルスベクタワクチン市場-地理的洞察

北米の地域が世界のウイルスベクタワクチン市場で最大のシェアを占めています。この優位性は、先進的ヘルスケアインフラ、研究開発への多額の投資、主要製薬企業やバイオテクノロジー企業の存在に起因しています。また、アジア太平洋は、ヘルスケア投資の増加、感染症流行の増加、先進的治療オプションに対する意識の高まりにより、世界市場で最も速い成長を遂げると予測されています。

ウイルスベクタワクチン市場-競合情勢

効果的で即応性の高いワクチンに対する世界の需要の高まりが、技術革新と戦略的投資の原動力となっています。企業各社は、急増する需要に対応するため、ベクタ設計の強化、安全性プロファイルの改善、製造能力の拡大に注力しています。研究機関や政府機関との提携は、開発と薬事承認を加速させるために一般的です。さらに、新興感染症向けワクチンなど、各社は製品パイプラインの多様化を進めています。世界的プレゼンスを強化し、先進的なワクチンプラットフォームへのアクセスを高めるため、地域的な拡大や買収も進められています。

目次

第1章 ウイルスベクタワクチン市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 ウイルスベクタワクチンの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 ウイルスベクタワクチン産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長展望マッピング
  • 規制枠組み分析

第5章 ウイルスベクタワクチン市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 ウイルスベクタワクチン市場情勢

  • ウイルスベクタワクチン市場シェア分析（2024年）
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 ウイルスベクタワクチン市場-疾患別

  • 概要
    • 疾患別セグメントシェア分析
    • 感染症
    • がん
    • 遺伝性疾患
    • その他

第8章 ウイルスベクタワクチン市場-タイプ別

  • 概要
    • タイプ別セグメントシェア分析
    • アデノ随伴ウイルス（AAV）
    • アデノウイルス
    • レンチウイルス
    • レトロウイルス
    • その他

第9章 ウイルスベクタワクチン市場-エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 製薬会社とバイオ医薬品会社
    • 研究機関

第10章 ウイルスベクタワクチン市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析-ウイルスベクタワクチン産業

  • 競合ダッシュボード
    • 競合ベンチマーキング
    • 競合ポジショニング
  • 企業プロファイル
    • Advanced Bioscience Laboratories
    • Sanofi SA
    • CH Boehringer Sohn AG & Ko
    • Brammer Bio, LLC
    • GE Healthcare
    • Creative Biogene
    • Pfizer Inc.
    • Moderna Inc.
    • Sinovac BIoTech Ltd.
    • CSL Ltd.
    • Astra Zeneca plc
    • GSK plc
    • Serum Institute of India Pvt. Ltd.
    • Merck & Co. Inc.
    • Novasep
    • Charles River Laboratories
    • Waisman Biomanufacturing
    • uniQure NV
    • Creative-Biogene
    • Addgene
    • Aldevron
    • Thermo Fisher Scientific Inc.
    • Spark Therapeutics Inc.
    • その他

第12章 アナリストの全方位的展望

目次
Product Code: ANV5367

REPORT HIGHLIGHT

Viral vector vaccines market size was valued at US$ 850.43 Million in 2024, expanding at a CAGR of 15.93% from 2025 to 2032.

Viral vector vaccines use a harmless virus as a delivery system to introduce genetic material from a pathogen into the body. This genetic code instructs cells to produce a protein that triggers an immune response without causing disease. These vaccines mimic natural infection, training the immune system to recognize and fight the real virus if exposed later. They are widely used in preventing infectious diseases like COVID-19 and Ebola.

Viral Vector Vaccines Market- Market Dynamics

Increasing prevalence of infectious diseases to propel market demand

The rising incidence of infectious diseases such as COVID-19, influenza, and hepatitis is propelling the demand for effective vaccines. According to the World Health Organization (WHO), vaccines prevent 2 to 3 million deaths annually, highlighting their critical role in global health. In addition, continuous progress in genetic engineering has facilitated the development of more efficient viral vector vaccines. However, instances of adverse effects, although rare, have been reported, leading to public hesitance, which is predicted to hamper the market growth in the coming years. On the contrary, developing regions present significant growth opportunities due to improving healthcare infrastructure and rising awareness about vaccination.

Viral Vector Vaccines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.93% over the forecast period (2025-2032)

Based on Disease segmentation, infectious diseases was predicted to show maximum market share in the year 2024

Based on Type segmentation, adenovirus was the leading Type in 2024

On the basis of region, North America was the leading revenue generator in 2024

Viral Vector Vaccines Market- Segmentation Analysis:

The Global Viral Vector Vaccines Market is segmented on the basis of Disease, Type, End User, and Region.

The market is divided into four categories based on Disease: infectious diseases, cancer, genetic disorders, and others. The infectious diseases segment is expected to hold the major market share in the global viral vector vaccines market during the forecast period. This dominance is primarily driven by the high global burden of infectious diseases and the proven effectiveness of viral vector platforms in developing vaccines against them.

The market is divided into five categories based on Type: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, and others. The adenovirus segment is expected to account for the largest market share during the forecast period. This is mainly because adenoviruses are widely used due to their strong immunogenicity, ability to carry large genetic payloads, and suitability for rapid vaccine development.

Viral Vector Vaccines Market- Geographical Insights

The North America region holds the largest share of the global viral vector vaccines market. This dominance is attributed to its advanced healthcare infrastructure, substantial investments in research and development, and the presence of leading pharmaceutical and biotechnology companies. Besides, the Asia-Pacific region is projected to experience the fastest growth in the global market, driven by the increasing healthcare investments, a rising prevalence of infectious diseases, and growing awareness of advanced therapeutic options.

Viral Vector Vaccines Market- Competitive Landscape:

Rising global demand for effective and rapid-response vaccines is driving technological innovation and strategic investment. Companies are focusing on enhancing vector design, improving safety profiles, and expanding manufacturing capabilities to meet surging demand. Partnerships with research institutions and government bodies are common to accelerate development and regulatory approval. Additionally, players are diversifying product pipelines to include vaccines for emerging infectious diseases. Regional expansions and acquisitions are also being pursued to strengthen global presence and increase access to advanced vaccine platforms.

Recent Developments:

In June 2025, ImmunoPrecise Antibodies Ltd. identified a stable epitope common to all four dengue virus serotypes using its AI-powered LENSai(TM) platform. This breakthrough supports progress toward a universal dengue vaccine using epitope-based targeting.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Advanced Bioscience Laboratories
  • Sanofi S.A.
  • C.H. Boehringer Sohn AG & Ko
  • Brammer Bio, LLC
  • GE Healthcare
  • Creative Biogene
  • Pfizer Inc.
  • Moderna Inc.
  • Sinovac Biotech Ltd.
  • CSL Ltd.
  • Astra Zeneca plc
  • GSK plc
  • Serum Institute of India Pvt. Ltd.
  • Merck & Co. Inc.
  • Novasep
  • Charles River Laboratories
  • Waisman Biomanufacturing
  • uniQure N.V.
  • Creative-Biogene
  • Addgene
  • Aldevron
  • Thermo Fisher Scientific Inc.
  • Spark Therapeutics Inc.
  • Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

  • Infectious Diseases
  • Cancer
  • Genetic Disorders
  • Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adeno-associated virus (AAV)
  • Adenovirus
  • Lentivirus
  • Retrovirus
  • Others

GLOBAL VIRAL VECTOR VACCINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

GLOBAL VIRAL VECTOR VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Viral Vector Vaccines Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Viral Vector Vaccines Market Snippet by Disease
    • 2.1.2. Viral Vector Vaccines Market Snippet by Type
    • 2.1.3. Viral Vector Vaccines Market Snippet by End User
    • 2.1.4. Viral Vector Vaccines Market Snippet by Country
    • 2.1.5. Viral Vector Vaccines Market Snippet by Region
  • 2.2. Competitive Insights

3. Viral Vector Vaccines Key Market Trends

  • 3.1. Viral Vector Vaccines Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Viral Vector Vaccines Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Viral Vector Vaccines Market Opportunities
  • 3.4. Viral Vector Vaccines Market Future Trends

4. Viral Vector Vaccines Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Viral Vector Vaccines Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Viral Vector Vaccines Market Landscape

  • 6.1. Viral Vector Vaccines Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Viral Vector Vaccines Market - By Disease

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease, 2024 & 2032 (%)
    • 7.1.2. Infectious Diseases
    • 7.1.3. Cancer
    • 7.1.4. Genetic Disorders
    • 7.1.5. Others

8. Viral Vector Vaccines Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 8.1.2. Adeno-associated virus (AAV)
    • 8.1.3. Adenovirus
    • 8.1.4. Lentivirus
    • 8.1.5. Retrovirus
    • 8.1.6. Others

9. Viral Vector Vaccines Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 9.1.2. Pharmaceutical and Biopharmaceutical Companies
    • 9.1.3. Research Institutes

10. Viral Vector Vaccines Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Viral Vector Vaccines Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Viral Vector Vaccines Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Viral Vector Vaccines Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Viral Vector Vaccines Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Viral Vector Vaccines Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Viral Vector Vaccines Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Advanced Bioscience Laboratories
    • 11.2.2. Sanofi S.A.
    • 11.2.3. C.H. Boehringer Sohn AG & Ko
    • 11.2.4. Brammer Bio, LLC
    • 11.2.5. GE Healthcare
    • 11.2.6. Creative Biogene
    • 11.2.7. Pfizer Inc.
    • 11.2.8. Moderna Inc.
    • 11.2.9. Sinovac Biotech Ltd.
    • 11.2.10. CSL Ltd.
    • 11.2.11. Astra Zeneca plc
    • 11.2.12. GSK plc
    • 11.2.13. Serum Institute of India Pvt. Ltd.
    • 11.2.14. Merck & Co. Inc.
    • 11.2.15. Novasep
    • 11.2.16. Charles River Laboratories
    • 11.2.17. Waisman Biomanufacturing
    • 11.2.18. uniQure N.V.
    • 11.2.19. Creative-Biogene
    • 11.2.20. Addgene
    • 11.2.21. Aldevron
    • 11.2.22. Thermo Fisher Scientific Inc.
    • 11.2.23. Spark Therapeutics Inc.
    • 11.2.24. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us